Answers are grounded in this paper and cite their sources.
This Viewpoint explores and provides policy recommendations for the Cell and Gene Therapy Access Model recently launched by the US Centers for Medicare & Medicaid Services (CMS), which aims to increase access to Medicaid recipiencts with rare and severe diseases.
No takes yet. Share an insight, caveat, or question.
Ballreich et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: